Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy.
Alessia CimadamoreAntonio Lopez-BeltranFrancesco MassariMatteo SantoniRoberta MazzucchelliMarina ScarpelliAndrea B GalosiLiang ChengRodolfo MontironiPublished in: Future oncology (London, England) (2020)